Good And Bad News For Genzyme MS Drugs At NICE: Aubagio In; Lemtrada Out For Now
This article was originally published in The Pink Sheet Daily
Executive Summary
Genzyme had a mixed few days with its MS drugs at NICE, with Aubagio finally succeeding but Lemtrada struggling on the back of a tough benefit/risk profile.
You may also be interested in...
NICE’s Tecfidera Restrictions In MS Leave It Fighting For U.K. Market Share
Biogen Idec get nod after providing more data, but restrictions imposed mean Tecfidera is unlikely to leap ahead of a packed field.
NICE's Unrestricted MS Indication For Lemtrada Could Boost It Ahead Of Rivals
Though not totally convinced about long-term effectiveness and patient adherence, NICE's decision not to restrict Lemtrada's indication could place it ahead of Gilenya and Tysabri for relapsing-remitting multiple sclerosis.
Biogen’s Tecfidera Hit At NICE By Data Shortage, Functional Unblinding
NICE has demanded more data and analyses for Biogen Idec’s MS champion, Tecfidera, before it clears a drug expected to be a worthy opponent for Novartis’ Gilenya.